Introduction
Fungal pathogens have a devastating impact on human health worldwide. They infect billions of people annually, with a substantial fraction of these infections manifesting as serious, life-threatening disease. Over 1.5 million deaths per year are attributed to fungal pathogens, making them a leading cause of human mortality (Brown et al., 2012) . The most vulnerable populations are those with reduced immune function, such as those undergoing immunosuppressive therapies for cancer or organ transplantation, or those individuals suffering from HIV. Candida spp. are among the top etiological agents of opportunistic fungal infections in humans. Among these, Candida albicans is the most prevalent, responsible for 90-100% of superficial mucosal infections and 40-70% of disseminated infections (Pappas et al., 2009; Pfaller and Diekema, 2010) . These illnesses also pose a significant economic burden, as conservative estimates suggest that treatment costs exceed $2.6 billion in the United States alone (Wilson et al., 2002) . Thus, there is an urgent requirement to understand the regulatory control of C. albicans pathogenesis and to develop more effective treatments.
The relatively close evolutionary relationship that fungi share with their human hosts greatly limits the number of sufficiently divergent targets that can be exploited for drug development. There are only three classes of antifungals for the treatment of invasive fungal infections, and the clinical utility of these drugs is limited by severe host toxicity and by the rapid emergence of drug resistance (Denning and Hope, 2010; Brown et al., 2012) . Currently, azoles are the most widely deployed class of antifungal due to their favourable pharmacokinetics and safety profile. They remain the drug of choice as an initial therapy for most fungal infections and are recommended as prophylaxis for high-risk patients (Walsh et al., 2008; Pappas et al., 2009; Perfect et al., 2010) . However, due to the fungistatic nature of azoles, there exists strong directional selective pressures for the evolution of resistance (Anderson, 2005; CDC, 2013) . There has also been an increased incidence in infections caused by intrinsically azole-resistant fungal species, including Candida glabrata, Candida krusei and Candida auris, creating major challenges for effective treatments (Miceli et al., 2011; Calvo et al., 2016) . Thus, new strategies are required to effectively control and prevent the development of drug resistance in current and emerging pathogens.
Targeting regulators of fungal cellular stress responses is an attractive emerging paradigm to enhance antifungal efficacy and improve clinical outcomes (Cowen, 2008; Veri and Cowen, 2014) . Hsp90 is a molecular chaperone that regulates the form and function of up to 20% of the proteome in the model yeast Saccharomyces cerevisiae, including key regulators of stress responses and cellular signaling (Taipale et al., 2010) . In fungi, targeting Hsp90 as an antifungal strategy holds considerable promise, given that it orchestrates crucial cellular responses to drug-induced stress and occupies central positions in many biological networks (Cowen and Lindquist, 2005; Taipale et al., 2010) . Inhibition of Hsp90 blocks the rapid emergence of drug resistance, transforms antifungals from fungistatic to fungicidal, abrogates resistance acquired by diverse mechanisms in clinical strains and renders resistant pathogens responsive to treatment in multiple infection models Singh et al., 2009 ). Even C. albicans biofilms, which are notoriously difficult to clear due to their intrinsic drug resistance, can be effectively eliminated with the combination of azoles and Hsp90 inhibitors (Robbins et al., 2011) . Inhibition of Hsp90 also induces a transition from yeast to filamentous growth and attenuates virulence (Shapiro et al., 2009) , consistent with the importance of morphological flexibility for virulence (Noble et al., 2010) . Despite Hsp90 being an attractive therapeutic target for the treatment of fungal infections, significant challenges remain. While Hsp90 inhibitors have been shown to be effective against localized infection without host toxicity (Robbins et al., 2011) , there is considerable toxicity in a murine model of disseminated candidiasis, likely due to deleterious effects of inhibition of host Hsp90 . Therefore, exploiting Hsp90 as a therapeutic target will likely require alternative strategies to inhibit components of the Hsp90 chaperone network that are distinct between the pathogen and host, such as upstream regulators of Hsp90 function.
Although Hsp90 interacts with a large proportion of the proteome, it has a well-characterized role in regulating and stabilizing a wide variety of specific substrate proteins, commonly referred to as Hsp90 'clients' (Taipale et al., 2010) . These include steroid hormone receptors, kinases, E3 ubiquitin ligases and transcription factors (Picard et al., 1990; Taipale et al., 2012; . Its function and specificity are closely regulated by posttranslational modifications such as phosphorylation, acetylation, methylation, nitrosylation and sumoylation (Martinez-Ruiz et al., 2005; Mollapour et al., 2010; Diezmann et al., 2012; Robbins et al., 2012; Hamamoto et al., 2014) . Hsp90 acetylation has a profound impact on Hsp90 function. The acetylation state is regulated by the addition and removal of acetyl groups on lysine residues by lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). Many small molecule inhibitors of KDACs have been described, with several currently in clinical trials as anticancer agents (Dokmanovic et al., 2007) . In S. cerevisiae and C. albicans, inhibition of KDACs with the broad spectrum KDAC inhibitor Trichostatin A (TSA) abrogates azole resistance (Robbins et al., 2012) . Further, a KDAC inhibitor targeting the fungal Hos2 complex, MGCD290, displays synergistic activity with azoles and echinocandins against diverse C. albicans drug-resistant isolates (Pfaller et al., 2009; . In the pathogenic mold Aspergillus fumigatus, mutations in Hsp90 that mimic constitutive acetylation result in decreased azole resistance as well as decreased virulence in a mouse model of invasive aspergillosis (Lamoth et al., 2014) . The divergence between fungal and human KDACs is much greater than for Hsp90, suggesting that KDACs are an attractive alternative therapeutic target for the treatment of fungal infections.
Our previous work demonstrated that pharmacological inhibition of KDACs with TSA phenocopies Hsp90 inhibition in abrogating azole resistance of both S. cerevisiae and C. albicans (Robbins et al., 2012) . Further analysis of regulatory control of Hsp90 acetylation revealed that the key targets of TSA in S. cerevisiae are Rpd3 and Hda1, catalytic subunits of distinct KDAC complexes (Robbins et al., 2012) . S. cerevisiae Hsp90 is acetylated on lysine 27 and 270, and compromising KDACs impairs the stability and function of select Hsp90 client proteins, including the drug-resistance regulator calcineurin (Robbins et al., 2012) . Beyond the model yeast, many questions remain unanswered in the pathogen C. albicans. The KDACs responsible for mediating Hsp90 deacetylation and the sites of acetylation have yet to be identified in C. albicans, and the functional consequences for drug resistance and virulence have remained unknown.
In this study, we uncover key facets to the impact of KDACs on the C. albicans Hsp90 chaperone network. We identify three distinct KDAC complexes in C. albicans that have functionally redundant roles in regulating both basal tolerance to azoles and azole resistance, and further establish lysine residues K30 and K271 as critical acetylation sites on C. albicans Hsp90. Mutations of these residues that mimic constitutive acetylation or deacetylation lead to a decreased ability to chaperone client proteins and to alterations in downstream signalling pathways that compromise virulence. Further, we highlight the effectiveness of the KDAC inhibitor TSA in abrogating azole resistance of multiple Candida species that is attributable to diverse resistance mechanisms. Thus, we identify extensive functional redundancy between KDACs that deacetylate Hsp90, discover lysine residues on C. albicans Hsp90 that are subject to acetylation with important biological consequences and explore acetylation as a mechanism governing fungal drug resistance and morphogenesis with broad therapeutic potential.
Results
Hos2 physically interacts with Hsp90 in C. albicans, and enhances Hsp90's repressive effects on morphogenesis Recently, we showed that the KDACs Hda1 and Rpd3 orchestrate Hsp90 deacetylation in S. cerevisiae (Robbins et al., 2012) , however, the KDAC complex(es) responsible for deacetylating Hsp90 in C. albicans remain unknown. Chemical-genetic analyses in C. albicans identified components of the Set3 KDAC complex, Hos2 and Snt1, as genetic interactors with Hsp90 under diverse environmental conditions (Diezmann et al., 2012; O'Meara et al., 2016) , suggesting that this KDAC complex may regulate Hsp90 function. To explore the potential functional relationship further, we assessed whether we could detect a physical interaction between Hos2 and Hsp90. Using a strain harbouring C-terminally TAP-tagged Hos2, immunoprecipitation with IgG agarose co-purified both TAP-tagged Hos2 and endogenous Hsp90 (Fig. 1A, left panel) . For the control strain lacking TAP-tagged Hos2, Hsp90 was present in the input but not the immunoprecipitated fraction (Fig. 1A, left panel) . The interaction was confirmed in a reciprocal immunoprecipitation using crosslinked agarose beads to which a highly specific anti-HA antibody is covalently immobilized. In a strain with Hsp90 C-terminally HA tagged, both Hsp90 and TAP-tagged Hos2 co-purified, however, this interaction was not observed with the untagged Hsp90 control strain (Fig. 1A, right panel) . Thus, Hos2 and Hsp90 physically interact in C. albicans.
Both Hos2 and Hsp90 exert a repressive effect on C. albicans morphogenesis. The Hos2 KDAC complex negatively regulates filamentation such that HOS2 homozygous deletion mutants display enhanced filamentation at the elevated temperature of 378C (Hnisz et al., 2010; Zacchi et al., 2010) . Genetic or pharmacological compromise of Hsp90 function leads to enhanced filamentation in the absence of elevated temperature (Shapiro et al., 2009) , implicating this chaperone as a key temperature sensor that governs C. albicans morphogenesis (Shapiro et al., 2009; Shapiro and Cowen, 2010) .
Based on our observation that Hos2 physically interacts with Hsp90, we hypothesized that Hos2 may regulate Hsp90 function, which in turn would impact morphogenesis. To test this hypothesis, we performed genetic epistasis experiments. We employed a strain of C. albicans where we could genetically deplete HSP90 using a maltose-inducible, glucose-repressible promoter system (MAL2p-HSP90/hsp90D). Notably, even when this strain is grown on medium with maltose as the sole carbon source, Hsp90 levels are still much lower than that observed in a wild-type strain (Shapiro et al., 2009) . Replacing the native HSP90 promoter with the MAL2 promoter did not cause filamentation in maltosecontaining liquid medium at 308C, and patches of cells remained smooth on solid medium (Fig. 1B and C) . Upon further depletion of HSP90 by culturing the MAL2p-HSP90/hsp90D cells in the presence of glucose, filaments began to form in liquid at 308C, although to a minimal degree. Additionally, the cells exhibited smooth patches when cultured on solid medium ( Fig. 1B and  C) . Similarly, a HOS2 homozygous deletion mutant remained as yeast in liquid medium, and exhibited smooth patches on solid medium at 308C (Fig. 1B and  C) . However, when HOS2 was deleted from the MAL2p-HSP90/hsp90D strain, we observed enhanced filamentation in liquid medium in the presence of both maltose and glucose at 308C relative to the parental strains (Fig.  1B) . Further, patches of MAL2p-HSP90/hsp90D hos2D/ hos2D cells exhibited a wrinkly colony morphology on solid medium when grown at 308C (Fig. 1C) . These observations support our model that Hos2 positively regulates Hsp90 function, such that deletion of this KDAC compromises Hsp90 function resulting in enhanced filamentation.
Hos2, Hda1, Rpd3 and Rpd31 mediate azole resistance in C. albicans In S. cerevisiae, Hda1 and Rpd3 are key KDACs that govern azole resistance by regulating Hsp90 deacetylation (Robbins et al., 2012) . However, the KDAC(s) that deacetylate Hsp90 in C. albicans and enable azole resistance had not been previously identified. We systematically deleted genes encoding catalytic subunits of KDAC complexes from a mutant lacking the ergosterol biosynthesis gene ERG3. The erg3D/erg3D mutant is unable to produce a toxic sterol intermediate in response to azole exposure, and has an azole resistance phenotype that is exquisitely dependent on Hsp90 (Cowen and Lindquist, 2005; Cowen et al., 2006) , providing a powerful background with which to identify the KDAC complexes that modulate Hsp90 function and azole resistance. We first chose to investigate Hos2 based on our findings that it physically interacts with Hsp90 and that it represses morphogenesis (Fig. 1) . Deletion of HOS2 had no impact on erg3-mediated azole resistance ( Fig. 2A) . We also examined Hda1 and Rpd3 based on their roles in regulating azole resistance in S. cerevisiae (Robbins et al., 2012) . Homozygous deletion of RPD3 or HDA1 did not reduce erg3-mediated azole resistance, nor did combined deletion of HOS2, RPD3 and HDA1 ( Fig. 2A) , suggesting that there is additional functional redundancy in the KDACs governing azole resistance in C. albicans.
Consistent with the possibility of additional functional redundancy, we identified a second homolog of S. cerevisiae RPD3 in C. albicans, called RPD31. This duplication appears only in the CTG clade. We were unable to delete RPD31 in the KDAC mutant backgrounds and thus constructed a tetracycline-repressible RPD31 conditional expression strain, allowing for transcriptional repression of RPD31 by the tetracycline analog doxycycline (DOX) (Fig. 2B) . Replacing the native RPD31 promoter with the tetO promoter had no impact on erg3-mediated azole resistance on its own or in the context of the erg3D/erg3D hda1D/hda1D rpd3D/rpd3D mutant, but abrogated azole resistance of the erg3D/erg3D hda1D/hda1D rpd3D/rpd3D hos2D/hos2D mutant in the presence of DOX ( Fig. 2A) . This also converted fluconazole from fungistatic to fungicidal, as shown by the lack of growth on solid medium following drug exposure and by monitoring colony forming units over time ( Fig. 2A , right panel, Supporting Information Fig. S1 ). Notably, azole resistance was partially reduced in the KDAC depletion strain even in the absence of DOX ( Fig. 2A) , possibly reflecting the misregulation of RPD31 transcript under the heterologous tetO promoter (Fig. 2B) . To validate that the observed phenotype was due to depletion of RPD31, the tetO-RPD31 allele was complemented by replacing the tetO promoter with the wild-type RPD31 promoter (WTp-RPD31). This restored RPD31 transcript to near wild-type levels and rendered RPD31 expression independent of perturbation by DOX (Fig. 2B) . The complemented strain regained fluconazole resistance and demonstrated the same phenotype as all other parental strains with a functional RPD31, confirming that the loss of fluconazole resistance is indeed due to depletion of RPD31 in the erg3D/erg3D hda1/hda1D rpd3D/rpd3D hos2D/hos2D background ( Fig. 2A and Supporting Information Fig. S1 ). These results indicate that the collective genetic impairment of HDA1, HOS2, RPD3 and RPD31 is required to abrogate Hsp90-dependent azole resistance. Moreover, it identifies divergence in the KDACs required to regulate Hsp90 function between S. cerevisiae and C. albicans.
Given that a predominant function of KDACs is to deacetylate lysines in core histones and thereby regulate gene expression (Kurdistani and Grunstein, 2003) , we tested whether compromising KDAC function reduced Hsp90 expression levels as opposed to regulating Hsp90 function posttranslationally. By Western blot, we observed that Hsp90 protein levels were not altered in the erg3D/erg3D hda1/hda1D rpd3D/rpd3D hos2D/ hos2D tetO-RPD31/rpd31D mutant strain in the presence of DOX compared to the wild-type strain (Fig. 2C ), indicating that these KDACs do not regulate Hsp90 protein expression or stability. This is consistent with previous findings that pharmacological inhibition of KDACs by TSA impairs Hsp90 protein function, but does not reduce Hsp90 transcript or protein levels in S. cerevisiae or C. albicans (Robbins et al., 2012) . Collectively, these results highlight an expansion of KDACs required to control Hsp90 at the posttranslational level in this fungal pathogen.
Hos2, Hda1, Rpd3 and Rpd31 mediate azole tolerance in C. albicans
To determine whether the KDAC-dependent azole resistance is a general phenomenon or restricted to the erg3D/erg3D mutant background, we re-introduced a wild-type ERG3 allele into the erg3D/erg3D mutants to test the impact of KDAC depletion on basal fluconazole tolerance in cells with a functional Erg3 enzyme. As expected, the complemented erg3D/erg3D1ERG3 strain was susceptible to azoles and displayed growth similar to that of a wild-type strain. As before, the hda1/hda1D A. Hsp90 and Hos2 physically interact as measured by co-immunoprecipitation of Hsp90 with Hos2-TAP. Left panel: Hos2-TAP was immunoprecipitated using IgG sepharose and Hsp90 was co-purified. Protein A domains were removed by TEV cleavage in the IP samples. The asterisk indicates the size of Hos2-TAP prior to TEV cleavage (82 kDa). The filled diamond indicates the size of Hos2-TAP postcleavage (55 kDa). Hsp90 was not recovered in the immunoprecipitation with IgG agarose in control cells harbouring untagged Hos2. Right panel: Hsp90-HA was immunoprecipitated using HA agarose and Hos2 co-purified. Hos2-TAP was not recovered in the immunoprecipitation with HA agarose in control cells harbouring untagged Hsp90. B. Deletion of HOS2 enhances filamentation observed with genetic perturbation of HSP90. Strains were grown in liquid-rich medium with 2% maltose (top panel) or 1% maltose and 1% glucose (bottom panel) as the carbon source for 7 h at 308C. Images are representative of biological triplicates. Note that the MAL2p-HSP90/hsp90D hos2D/hos2D strain is one of two independently generated transformants that were tested. Both showed an identical filamentation phenotype. C. Combined deletion of HOS2 and genetic perturbation of HSP90 causes wrinkly colony morphology. Strains were grown on rich solid medium with 2% maltose as the carbon source for 48 h at 308C. Images of patches are representative of biological triplicates.
Hsp90 acetylation governs C. albicans pathogenicity 639 Molecular Microbiology, 103, rpd3D/rpd3D hos2D/hos2D tetO-RPD31/rpd31D mutant showed partial increase in azole susceptibility even in the absence of DOX, as reduced growth at concentrations above the minimum inhibitory concentration (MIC) was observed. However, based on the spotting assay for cidality, the cells were still viable in fluconazole in the absence of DOX. Combined deletion of HDA1, HOS2 and RPD3, and DOX-mediated transcriptional repression of RPD31 created a fungicidal combination with fluconazole ( Fig. 3) , as indicated by the lack of growth in spotting assays even after 48 h of incubation. These results confirm that the contribution of KDACs to azole tolerance and resistance is not limited to the erg3D/ erg3D mutant background, but rather a more general phenomenon.
Acetylation mutations in Hsp90 result in hypersensitivity to Hsp90 inhibitors
To further dissect the connection between KDACmediated azole resistance and Hsp90 acetylation in C. albicans, we aimed to identify the critical Fig. 3 . Hos2, Hda1, Rpd3 and Rpd31 mediate azole tolerance in C. albicans. Left panel: Fluconazole MIC assays were conducted in YPD medium without DOX (2) or with 1 mg ml 21 DOX. Growth was measured by absorbance at 600 nm after 72 h at 308C. Optical densities were averaged for duplicate measurements. Data were quantitatively displayed with colour using Treeview (see colour bar). Right panel: combined deletion of HDA1, HOS2 and RPD3, and DOX-mediated transcriptional repression of RPD31 creates a fungicidal combination with fluconazole. Cells from the MIC assays were then spotted onto YPD medium plate without drug and incubated at 308C for 48 h to assess viability. Fig. 2 . Hos2, Hda1, Rpd3 and Rpd31 mediate azole resistance in C. albicans.
A. Combined deletion of HDA1, HOS2 and RPD3, and DOX-mediated transcriptional repression of RPD31 reduces azole resistance of an erg3D/erg3D mutant. Left panel: Fluconazole MIC assays were conducted in YPD medium without DOX (2) or with 1 mg ml 21 DOX. Growth was measured by absorbance at 600 nm after 24 h at 308C. Optical densities were averaged for duplicate measurements. Data were quantitatively displayed with colour using Treeview (see colour bar). Right panel: combined deletion of HDA1, HOS2 and RPD3, and DOXmediated transcriptional repression of RPD31 creates a fungicidal combination with fluconazole. Cells from the MIC assays were spotted onto YPD agar without drug and incubated at 308C for 48 h to assess viability. B. RPD31 transcript level is repressed with DOX when under the control of tetO-repressible promoter system, and restored upon complementation with a native promoter. Strains were grown in the absence (black bars) or presence of 1 lg ml 21 DOX (white bars). RPD31 transcript levels were normalized to GPD1. Data are means 6 standard error for triplicate samples. C. Hda1, Rpd3, Hos2 and Rpd31 do not affect Hsp90 protein level. Strains were grown to log phase in the absence or presence of 1 lg ml 21 DOX. Western blots were hybridized with an antibody specific to C. albicans Hsp90 or with an antibody specific to Cdc28. Cdc28 protein levels are used as a loading control.
Hsp90 acetylation governs C. albicans pathogenicity 641 acetylation sites on Hsp90 that regulate its chaperoning abilities. The two candidate residues that we focused on were lysine residues K30 and K271. Changes in acetylation status of the corresponding residues were found to affect Hsp90 function in both the model yeast S. cerevisiae and the pathogenic mold A. fumigatus (Robbins et al., 2012; Lamoth et al., 2014) . Acetylation mimic (lysine to glutamine, K30Q and K271Q) and deacetylation mimic (lysine to arginine, K30R and K271R) mutations for these Hsp90 residues were introduced into a strain where the remaining wild-type HSP90 allele was under the control of the tetO repressible promoter system (Fig.  4A ), allowing us to assay the impact of these mutated Hsp90 residues upon depletion of the wildtype Hsp90 protein. Acetylation mutations at either one or both candidate residues did not alter Hsp90 protein levels relative to the wild type in the absence of DOX (Fig. 4B) . Further, transcriptional repression of the wild-type HSP90 allele reduced the expression of Hsp90 in all strains regardless of the point mutations that were present, indicating these mutations do not affect the expression or stability of the protein.
To explore the impact of the acetylation mutations on Hsp90 function we performed drug susceptibility assays in the presence of the Hsp90 inhibitor geldanamycin (GdA). We predicted that mutating Hsp90 lysine residues that are important for its function would confer increased sensitivity to GdA. Strains with a single acetylation mutation at either lysine 30 or lysine 271 were hypersensitive to GdA upon transcriptional repression of the wild-type allele (P < 0.001, ANOVA, Bonferroni's Multiple Comparison Test), and the phenotype was exacerbated when both residues were mutated (Fig. 4C) . This indicates that the acetylation status of both K30 and K271 influences Hsp90 function. Importantly, GdA hypersensitivity was seen with both the acetylation mimic and the deacetylation mimic mutants, suggesting that proper cycling of the posttranslational modification is required.
We then assessed whether lysine 30 and lysine 271 were the sole lysine residues important for mediating Hsp90-dependent azole resistance. Compared to the wild-type, lysine 30 and lysine 271 mutations in Hsp90 mimicking acetylation or deacetylation did not increase azole susceptibility (Fig. 4D) . Hence, the acetylation status at lysine 30 and lysine 271 in Hsp90 cannot be solely responsible for the increased azole sensitivity observed with the loss of KDAC function. This implicates either additional residues on Hsp90 that are regulated by acetylation or additional targets of KDACs that are important for azole resistance. Similar results were previously demonstrated in S. cerevisiae, where acetylation mutations of the corresponding residues resulted in compromised Hsp90 function, but were insufficient to reduce azole resistance (Robbins et al., 2012) .
Altered Hsp90 acetylation status leads to impaired Hsp90-dependent phenotypes and client protein function
Next, we addressed whether mutating the key lysine residues important for Hsp90 tolerance to GdA impacted Hsp90 dependent cellular processes. As a reporter for Hsp90 function, we examined the capacity of Hsp90 to repress C. albicans morphogenesis (Shapiro et al., 2009) . We reasoned that if Hsp90 function were compromised in strains harbouring HSP90 mutations that mimic constitutive acetylation or deacetylation, then a lower concentration of Hsp90 inhibitor would be sufficient to induce filamentation compared to that required for a wild-type strain. As a control, we included a strain where one allele of HSP90 was deleted and the other was under the control of the DOX-repressible promoter. Addition of 2 lg ml 21 of DOX induced morphogenesis of the tetO-HSP90/hsp90D strain in the absence of GdA, demonstrating that this level of DOX is sufficient to repress the expression of the tetO-HSP90 allele (Fig. 5) . In contrast, 2 lg ml 21 of DOX did not induce filamentous growth in the tetO-HSP90/HSP90 strain even in the presence of 1.25 lM GdA, demonstrating that a single allele of HSP90 is sufficient to maintain yeast form growth upon low levels of Hsp90 inhibition with GdA. We found that 1.25 lM GdA induced filamentation when both lysine 30 and lysine 271 were mutated to the constitutively acetylated or deacetylated forms upon DOXmediated transcriptional repression of the wild-type allele (Fig. 5 ). This suggests that the combined mutation of these residues is sufficient to partially compromise Hsp90 function relative to the wild-type allele. Consistent Fig. 4 . Acetylation mutations in Hsp90 result in hypersensitivity to the Hsp90 inhibitor geldanamycin (GdA) in C. albicans.
A. Schematic of Hsp90 domain structure indicating candidate acetylated lysine residues K30 and K271. Alleles carrying mutations at these residues (HSP90*) were introduced to a strain where the only other HSP90 allele is under the control of the tetO promoter system where transcriptional repression is achieved upon incubation with the tetracycline analog doxycycline (DOX). B. Acetylation mutations at K30 and K271 do not affect Hsp90 protein levels. Cells were grown to mid-log phase in the absence or presence of 2 mg ml 21 DOX, then harvested for protein extraction and subsequent Western blot analysis. Tubulin is used as a loading control. C. Acetylation mutations at K30 or K271 result in hypersensitivity to Hsp90 inhibition with GdA. Cells were grown for 24 h at 308C in YPD medium containing 2 mg ml 21 DOX with or without GdA. Growth was measured by optical density at 600 nm. The asterisks represent P<0.001 compared to the tetO-HSP90/HSP90 strain grown in DOX. D. Acetylation mutations at K30 and K271 do not increase azole susceptibility. Left panel: Fluconazole MIC assays were conducted in YPD medium with 2 mg ml 21 DOX. Growth was measured by absorbance at 600 nm after 24 h at 308C. Optical densities were averaged for duplicate measurements. Data were quantitatively displayed with colour using Treeview (see colour bar). Right panel: Cells from the MIC assays were then spotted onto YPD medium plate without drug and incubated at 308C for 48 h to assess viability.
Hsp90 acetylation governs C. albicans pathogenicity 643 A. Cells were grown at 308C in YPD rich medium in the absence or presence of 1 mg ml 21 DOX for 6 h, at which point cells were imaged by DIC microscopy. Images are representative fields of view. B. Cells grown in the same condition as in (A) were used for quantitative RT-PCR. HWP1 transcript levels are normalized to GPD1. Data are means 6 standard error for triplicate samples. The asterisk represents P < 0.001 compared to the wild-type in the same condition, ANOVA, Bonferroni's Multiple Comparison Test.
Hsp90 acetylation governs C. albicans pathogenicity 645 with previous results, both the acetylated and deacetylated form of Hsp90 resulted in compromised Hsp90 function, highlighting the importance of cycling between different acetylation states.
To evaluate whether the redundant KDAC complexes important for mediating azole resistance are also important for morphogenesis, we monitored C. albicans filamentation by microscopy and quantified transcript levels of the hyphal-specific gene HWP1 in our KDAC mutants. In the presence or absence of DOX, both the wild type and erg3D/erg3D1ERG3 strain remained as yeast upon growth in rich medium (Fig. 6A) . Collective genetic compromise of HDA1, RPD3 and HOS2 or HDA1, RPD3 and RPD31 led to some induction of HWP1 transcript levels but no discernable effects on filamentous growth (Fig. 6A and B) . However, in the erg3D/erg3D1ERG3 hda1D/hda1D rpd3D/rpd3D hos2D/ hos2D tetO-RPD31/rpd31D strain, filamentation and elevated levels of HWP1 were observed in the presence or absence of DOX ( Fig. 6A and B) . Replacing the tetO promoter with the wild-type RPD31 promoter (WTp-RPD31) abrogated the filamentation phenotype ( Fig. 6A  and B) . Thus, the redundant KDAC complexes important for mediating azole resistance are also all important for orchestrating C. albicans filamentation.
Next, we tested glucocorticoid receptor (GR) activation to assess the impact of lysine 30 and lysine 271 on Hsp90 client protein function. GR is a well characterized Hsp90 client protein in mammals, and has been used extensively in S. cerevisiae as a reporter of Hsp90 function (Pratt et al., 2004) . To take advantage of the existing system, we used S. cerevisiae strains in which C. albicans HSP90 was expressed from a plasmid as the sole source of Hsp90 in the cell (Fig. 7A) (Nathan and Lindquist, 1995) . Consistent with our C. albicans results (Fig. 4B) , we confirmed that the Hsp90 protein levels remained constant regardless of acetylation or deacetylation mimic mutations (Fig. 7B) , and that the strains containing mutations in both lysine 30 and lysine 271 were hypersensitive to Hsp90 inhibition compared to wild-type ( Fig. 7C ; P < 0.001). We then introduced a plasmid that contains the mouse GR under the control of a constitutive promoter as well as a lacZ reporter gene under the control of glucocorticosteroid response elements (Nathan and Lindquist, 1995) . When Hsp90 is functional and can assist in proper folding of GR, addition of the hormone deoxycorticosterone leads to activation of GR, allowing it to translocate to the nucleus and bind to glucocorticosteroid response elements in the promoter of its target genes, thereby activating their transcription. Testing GR activation in response to deoxycorticosterone in the acetylation mutants revealed a similar trend as the GdA sensitivity assay (Fig. 7D) . Acetylation mutations resulted in significantly reduced GR activation compared to the wild-type CaHSP90 (P < 0.001), with the double mutants having the most severe phenotype.
Finally, we examined the impact of these acetylation mutations on the escape of C. albicans from host immune cells via induction of macrophage pyroptosis. Fig. 7 . Acetylation mutations at lysine 30 and 271 of C. albicans HSP90 result in hypersensitivity to the Hsp90 inhibitor geldanamycin and impaired activation of glucocorticoid receptor in S. cerevisiae. A. Schematic representation of introducing C. albicans HSP90 into an S. cerevisiae strain where it serves as the only source of HSP90 in the cell. B. Acetylation mutations do not affect Hsp90 protein level. Western performed on S. cerevisiae strains carrying either the wild-type or various acetylation mutant alleles of C. albicans HSP90. Proteins were extracted from log phase growing cells. Tubulin level is used as loading control. C. Acetylation mutations result in hypersensitivity to the Hsp90 inhibitor geldanamycin. Area under the curve calculated for growth curves over 72 h at 308C in YPD rich medium with or without geldanamycin. Growth was measured by absorbance at 600 nm. D. Hsp90 acetylation mutations impair glucocorticoid receptor activity. Log phase cells were diluted to OD 600 of 0.2 and grown for 1 h in YPD at 308C with or without 10 mM deoxycorticosterone. b-Galactosidase activity was measured by incubating the cells for 15 min with CPRG substrate, and taking absorbance at 578 nm. Fold induction was calculated by taking the ratio of the deoxycorticosterone induced cells over the uninduced. Previously, we demonstrated that multiple Hsp90 genetic interactors, including the Snt1 lysine deacetylase, are required for induction of pyroptosis (O'Meara et al., 2016) , highlighting the importance of Hsp90 in this process. Here, we infected bone-marrow-derived macrophages expressing an mCherry-labelled ASC protein that oligomerizes upon NLRP3-dependent pyroptosis (Franklin et al., 2014) , and quantified the ability of the Hsp90 acetylation mutants to induce macrophage pyroptosis. As expected, depletion of Hsp90 with DOX resulted in decreased pyroptosis rates (Fig. 8) . Consistent with the previous results, we found that when both lysine 30 and lysine 271 were mutated to the constitutively acetylated or deacetylated forms, the strains had a significant reduction in their ability to trigger pyroptosis upon transcriptional repression of the wild-type allele (Fig. 8) . There was no significant difference in pyroptosis between the strains in the absence of DOX. Thus, the proper regulation of acetylation states at both lysine 30 and lysine 271 is critical for Hsp90 function.
Investigating the role of Hsp90 and KDACs on azole resistance of different Candida species, clinical isolates and diverse azole-resistant mutants
More than 90% of invasive Candida infections are attributed to five species: C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei (Pfaller and Diekema, 2010) . This motivated our expanded analysis of the impact of inhibition of Hsp90 and KDAC function on azole resistance of other Candida species. All Candida species tested displayed high levels of fluconazole resistance, as measured by MIC assays (Fig. 9A, left  panel) . For C. albicans, C. tropicalis and C. guillermondii, resistance to fluconazole was abrogated upon inhibition of Hsp90 with GdA or KDACs with TSA (Fig. 9A , middle and right panels). However, for C. glabrata, C. krusei and C. parapsilosis, fluconazole susceptibility was not altered upon inhibition of Hsp90 or KDACs using doses of inhibitors fourfold higher than that used for C. albicans (Fig. 9A, middle and right panels) . This suggests that the impact of Hsp90 on azole resistance varies among different Candida species, or that some Candida species are resistant to Hsp90 inhibitors. Notably, pharmacological inhibition of Hsp90 phenocopies pharmacological inhibition of KDACs in all species tested, suggesting that Hsp90 function is likely regulated at the posttransnlational level in diverse Candida species to control cellular responses to azole-induced stress.
Next, we tested the impact of Hsp90 and KDACs on C. albicans azole resistance that was acquired by diverse mutations. For both S. cerevisiae and C. albicans, resistance to the azoles acquired by loss of function of the ergosterol biosynthetic enzyme Erg3 is highly dependent on both Hsp90 and KDAC function (Cowen and Lindquist, 2005; Cowen et al., 2006; LaFayette et al., 2010; Robbins et al., 2012) . In S. cerevisiae, strains that have acquired azole resistance solely through overexpression of the drug transporter Pdr5 are Hsp90 and KDAC independent (Cowen and Lindquist, 2005; Robbins et al., 2012) , yet a detailed appreciation of which C. albicans azole-resistance mechanisms depend on Hsp90 or KDAC function has remained lacking. First, we explored the impact of Hsp90 and KDACs on azole resistance acquired by overexpression of the drug target Erg11. Hyperactive mutations of the transcription factor gene UPC2 result in constitutively high levels of ERG11, thereby enabling azole resistance (Dunkel et al., 2008) . We discovered that azole resistance of mutants harbouring homozygous hyperactive mutations
A643T was reduced upon inhibition of Hsp90 or KDACs (Fig. 8B) . This is consistent with a previous report that demonstrated a UPC2 A643V hyperactive mutation was dependent on Hsp90 function to enable azole resistance (Hill et al., 2015) . Therefore, azole resistance acquired by overexpression of the drug target ERG11 is dependent on Hsp90 and KDAC function. We extended our analysis of the impact of perturbation of Hsp90 or KDACs on azole resistance to strains that overexpress drug efflux pumps. Expression of the Fig. 9 . Hsp90 and KDACs regulate azole resistance in distinct Candida species, and in multiple C. albicans azole-resistant isolates.
A. Fluconazole MIC assays for diverse Candida species were conducted in YPD medium with no inhibitor (2), with the Hsp90 inhibitor geldanamycin (GdA, 5 lM for C. albicans, C. tropicalis and C. guillermondii; 20 lM for C. glabrata, C. krusei and C. parapsilosis), or with the KDAC inhibitor trichostatin A (TSA, 6 lg ml 21 for C. albicans, C. tropicalis and C. guillermondii; 24 lg ml 21 for C. glabrata, C. krusei and C. parapsilosis). Growth was measured by absorbance at 600 nm after growth for 48 h at 308C. Optical densities were averaged for duplicate measurements and normalized relative to the no drug control for each strain. Data was quantitatively displayed with colour using Treeview (see colour bar). B. Hsp90 and KDACs regulate fluconazole susceptibility of specific C. albicans azole-resistant mutants. Fluconazole MIC assays were conducted in YPD medium with no inhibitor (2), with the Hsp90 inhibitor geldanamycin (GdA, 5 lM), or with the KDAC inhibitor trichostatin A (TSA, 6 lg ml 21 ). Growth was measured as in part A. CI-S and CI-R represent a matched set of clinical isolates that showed sensitivity and resistance to fluconazole respectively. The TAC1 allele in CI-R contains an N972D point mutation that confers azole resistance. 'F' and 'G' represent distinct sets of matched clinical isolates that over time acquired fluconazole resistance due to mutations in MRR1. The MRR1 allele in F5 contains a P683S point mutation, and the MRR1 allele in G5 contains a G977V point mutation.
ABC transporter genes CDR1 and CDR2 is regulated by the transcription factor Tac1 (de Micheli et al., 2002) , and TAC1 hyperactivating mutations are frequently identified in clinical isolates. We assessed fluconazole resistance in the presence and absence of GdA or TSA for clinical isolates (CI) that had evolved fluconazole resistance due to a gain-of-function mutation in TAC1 (Znaidi et al., 2007) . We also tested strains in which TAC1 alleles from azole-susceptible and azole-resistant clinical isolates were cloned into a laboratory-derived TAC1 homozygous deletion mutant, such that the only mutation in this strain was from the gain-of-function mutation in TAC1 (Znaidi et al., 2007) . Both the clinical isolate harbouring the gain-of-function TAC1 allele (CI-R) and the laboratory strain containing the gain-of-function TAC1 allele (TAC1 CI-R /tac1) displayed elevated fluconazole resistance relative to a wild-type laboratory strain (SC5314) or a clinical isolate without the TAC1 mutation (CI-S) (Fig. 9B ). This resistance was not reduced upon the addition of GdA or TSA. Although hyperactivity of drug efflux transporters could simply cause increased efflux of GdA or TSA, we previously established that genetic depletion of Hsp90 does not reduce resistance acquired by overexpression of ABC-transporters in S. cerevisiae (Cowen and Lindquist, 2005) . Hence, azole resistance caused by gain-of-function mutations in TAC1 is likely independent of Hsp90 and KDACs. Finally, we investigated the impact of inhibition of Hsp90 or KDACs on fluconazole resistance acquired by overexpression of drug transporter Mdr1. Multidrug resistance regulator (Mrr1) is a transcription factor that governs the expression of MDR1 (Morschhauser et al., 2007) . We assessed fluconazole susceptibility of two different matched sets of clinical isolates (isolates F and isolates G) that had acquired fluconazole resistance due to overexpression of MDR1. MRR1 alleles from the resistant clinical isolates were cloned into laboratory strains of C. albicans such that the only mutation in the strain was that in MRR1 (Morschhauser et al., 2007) . Similar to what was observed with the Tac1 mutants, mutations in MRR1 caused increased levels of fluconazole resistance that was unaffected by GdA or TSA (Fig. 9B) . Thus, fluconazole resistance acquired by drug pump overexpression is likely independent of Hsp90 or KDACs, consistent with findings from S. cerevisiae.
Discussion
The molecular chaperone Hsp90 interacts with a large network of client proteins that transduce diverse signals to mediate key biological processes in the cell. Regulation of Hsp90 through posttranslational modifications such as acetylation modulates the interactions between Hsp90 and client proteins and the functional consequences thereof (Bali et al., 2005; Kovacs et al., 2005; Taipale et al., 2010; Robbins et al., 2012) . Our study provides a detailed molecular analysis of the KDACs that modulate Hsp90 function and azole resistance in the fungal pathogen C. albicans, and how these modifications contribute to host-pathogen interactions. We show extensive functional redundancy between the KDACs Hda1, Rpd3, Hos2 and Rpd31, which regulate azole tolerance and resistance in C. albicans. The impact of KDACs on Hsp90 is likely through altering chaperone function, as point mutations of key lysine residues that mimic acetylation or deacetylation results in a reduced functional capacity of Hsp90 as indicated by hypersensitivity to GdA, induction of filamentous growth in the absence of cues and impaired activation of Hsp90 client proteins such as GR. Notably, mutations of these residues did not alter fluconazole susceptibility, suggesting that there are other functionally important residues in Hsp90 or other targets of KDACs implicated in azole resistance that remain to be identified. KDAC inhibitors phenocopied Hsp90 inhibitors in reducing azole resistance of diverse Candida species, as well as for isolates harbouring distinct resistance mechanisms. Thus, our findings support the growing literature that acetylation of Hsp90 is an important mechanism of posttranslational control in the fungal kingdom, and highlight an expansion of the key KDACs that mediate this process in C. albicans.
Our extensive chemical genetic analysis highlights rewiring of the circuitry connecting KDACs and Hsp90 since the divergence of C. albicans and S. cerevisiae. Genetic interaction networks in C. albicans have identified multiple components of the Set3/Hos2 complex as genetic interactors of Hsp90 under diverse environmental conditions (Diezmann et al., 2012; O'Meara et al., 2016) , implicating this KDAC complex as a distinct regulator of Hsp90 function from those identified in S. cerevisiae (Robbins et al., 2012) . This resonates with the extensive rewiring of other regulatory networks between the two species, where orthologs of Hsp90 and other conserved regulators have evolved distinct connectivity over evolutionary time (Martchenko et al., 2007; Blankenship et al., 2010; Diezmann et al., 2012; VermaGaur et al., 2015; Childers et al., 2016) . Such rewiring events are often observed in virulence-related programs, likely reflecting adaptations to different ecological niches by the model yeast and pathogen. The fact that four KDAC genes, RPD3, RPD31, HDA1 and HOS2, had to be depleted to reduce azole resistance demonstrates a remarkable level of functional redundancy. This is distinct from a previous study that showed in a different strain background, deletion of either RPD3 or HDA1 alone was sufficient to enhance the efficacy of azoles and block the emergence of azole resistance (Li et al., 2015) . In S. cerevisiae, there is typically a division of labour among KDACs, with these complexes carrying out largely non-overlapping functions, both in terms of regulation of gene expression and general protein deacetylation (Kaluarachchi Duffy et al., 2012; Robyr et al., 2002) . Here, our results suggest that a set of KDACs have overlapping roles in azole resistance with remarkable functional redundancy. Similar genetic robustness has been described for the NAD 1 -dependent KDACs Hst1 and Sir2, where Sir2 can substitute for Hst1 in its absence to regulate gene expression programs in S. cerevisiae (Hickman and Rusche, 2007) . Whether the multiple KDAC complexes we identified as important regulators of azole resistance all control Hsp90 deacetylation simultaneously, or whether they merely compensate for one another when the function of one is compromised remains to be explored.
There is a remarkable complexity in the code of posttranslational modifications that control distinct aspects of Hsp90 function. Our results indicate that multiple lysine residues, including but not limited to lysine 30 and lysine 271, are regulated by acetylation to control the activity of the Hsp90 chaperone machinery. These residues were identified based on homology to known acetylation sites in other fungal species (Robbins et al., 2012; Lamoth et al., 2014) . Substitutions at key lysine residues that mimic acetylation (K to Q) or deacetylation (K to R) had similar phenotypic effects in all Hsp90 functional assays tested: susceptibility to GdA; induction of filamentous growth; GR activation or induction of macrophage pyroptosis. This suggests that it is not the acetylation state of the residue that matters, but rather the ability to cycle between the acetylated and deacetylated forms that is critical for proper Hsp90 function. The Hsp90 chaperone cycle is an incredibly dynamic process, where it associates and dissociates with cochaperones and client proteins, and is driven by ATP hydrolysis (Taipale et al., 2010; Li et al., 2012) . In mammalian cells, casein kinase 2 (CK2) phosphorylates Hsp90 at threonine 22, and both the phosphomimic mutations and mutations that prevent phosphorylation cause destabilization of Hsp90 client kinases and alteration of GR activity (Mollapour et al., 2011) , suggesting that the ability to cycle between phosphorylation states is key for proper Hsp90 function. Thus, our findings support the model that conformational changes that occur during the cycling between posttranslational states are necessary for optimal Hsp90 chaperoning of clients.
Targeting KDACs has emerged as a promising strategy for the treatment of several diseases, including haematological malignancies, cutaneous lymphomas and solid organ tumors (Bolden et al., 2006) . For the treatment of fungal infections, the broad spectrum KDAC inhibitor TSA increases susceptibility to azoles (Smith and Edlind, 2002) , and a fungal-specific inhibitor of Hos2 activity, MGCD290, is synergistic with azoles and echinocandins against multiple fungal pathogens ( Pfaller et al., 2009 Pfaller et al., , 2015 . In addition to using KDAC inhibitors as combination therapeutics with current antifungals, targeting KDACs themselves could provide therapeutic benefits on their own. The NAD 1 -dependent KDAC inhibitor nicotinamide has been shown to reduce fungal kidney burden in a mouse model of disseminated candidiasis (Wurtele et al., 2010) . Also, an rpd31D/rpd31D mutant has attenuated virulence in a mouse model of systemic infection (Lee et al., 2015) . Although we observed that some Candida species and some C. albicans clinical isolates maintained azole resistance in the presence of Hsp90 or KDAC inhibitors, targeting Hsp90 and KDACs may still possess great therapeutic potential against these organisms. We have demonstrated that inhibiting Hsp90 and KDAC function impedes the evolution of drug resistance Lindquist, 2005, Robbins et al., 2012) , that genetic reduction of C. albicans Hsp90 levels enhances the efficacy of azoles in a mouse model of disseminated infection , and that pharmacological compromise of Hsp90 function transforms antifungals from ineffective to highly efficacious in a mammalian model of biofilm formation (Robbins et al., 2011) . Our work presented in this manuscript suggests that an additional consequence of perturbation of Hsp90 function upon inhibition of KDACs manifests in terms of modulating the C. albicans morphogenetic program and impeding pyroptosis, which are key virulence attributes. If indeed KDAC inhibitors have efficacy by targeting virulence factors in C. albicans, they may offer many advantages such as minimizing the effects on the host mycobiome and reducing selective pressures for the evolution of resistance. Moving forward, the challenge lies in developing fungal-specific KDAC inhibitors that retain broad spectrum activity across multiple KDACs while minimizing host toxicity.
Experimental procedures

Strains and culture conditions
Archives of all yeast strains were maintained at 2808C in 25% glycerol. Strains used in experiments were maintained on solid (2% agar added) yeast extract peptone (YPD, 1% yeast extract, 2% bactopeptone, 2% glucose) at 48C for no more than one month. For experiments, yeast strains were routinely grown in either YPD medium or in synthetic defined medium (SD, 0.67% yeast nitrogen base, 2% glucose) supplemented with amino acids, unless otherwise indicated. Strains used in this study are listed in Supporting Information Table S1 . Strain construction is described in the Supporting Information text.
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Plasmid construction
Recombinant DNA procedures were performed according to standard protocols and their construction is described in the Supporting Information Text. Plasmids were sequenced to verify the absence of any nonsynonymous mutations. Plasmids used in this study are listed in Supporting Information Table S2 . Oligonucleotides used in this study are listed in Supporting Information Table S3 .
Minimum inhibitory concentration assays
Antifungal tolerance and resistance were determined in flat bottom, 96-well microtiter plates using a modified broth microdilution protocol as described LaFayette et al., 2010) . Dimethyl sulfoxide (DMSO, Sigma Aldrich Co.) was the solvent for the Hsp90 inhibitor GdA (ant-gl-5, Cedarlane) and the KDAC inhibitor TSA; DOX and fluconazole (Sequoia Research Products) were dissolved in sterile ddH 2 O. MIC tests were set up in a total volume of 0.2 ml/well with 2-fold dilutions of fluconazole. Plates were incubated in the dark for 24, 48 or 72 h. Optical density (OD) was determined at 600 nm using a spectrophotometer (Molecular Devices) and corrected for background from the corresponding medium. Each strain was tested in duplicate on at least two occasions. MIC data was quantitatively displayed with colour using the program Java TreeView 1.1.3 (http://jtreeview.sourceforge.net ). To test cidality, cells from the MIC plates were spotted on YPD agar plates using a spotter (Frogger, V&P Scientific, Inc.). Plates were photographed after 48 h of incubations at 308C.
Co-immunoprecipitation
To monitor the interaction between Hsp90 and Hos2, cells were grown overnight at 308C in YPD. Cells were diluted to OD 600 of 0.1 in 50 ml and grown at 308C to mid-log phase. Protein was harvested as described previously . In brief, cells were washed with sterile water and resuspended in 1 ml of lysis buffer J containing 20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2 and 20% glycerol, with one protease inhibitor cocktail (complete, EDTA-free tablet, Roche Diagnostics) per 10 ml, as well as 1 mM PMSF (EMD Chemicals) and 20 mM sodium molybdate (Sigma Aldrich Co.) added fresh before use. Cells were mechanically disrupted by adding acid-washed glass beads and bead beating twice for 4 min with a 10-min break on ice between cycles. Total collected lysates were cleared by centrifugation at 20 817g for 10 min at 48C and protein concentrations were determined by Bradford analysis. Anti-TAP immunoprecipitations were conducted as described previously . In brief, protein samples were diluted to 1.5 mg ml 21 in lysis buffer J with 0.2% tween. Protein was incubated with washed IgG agarose (Sigma Aldrich Co.) at 48C overnight. Unbound material was removed by three washes with lysis buffer J with 0.1% tween. Bound material was treated with AcTEV protease for 3 h, as per manufacturer's instructions (Invitrogen), to remove the protein A moiety from the TAP-epitope. Subsequently, supernatant was removed from the IgG agarose beads and was incubated with washed NiNTA agarose at 48C for 2 h to remove the AcTEV protease from the immunoprecipitated fraction. The supernatant was removed from the NiNTA agarose and was combined with one-sixth the volume of 63 SDS-PAGE sample buffer and was boiled for 5 min. Anti-HA immunoprecipiations were done using Pierce HA-Tag IP/Co-IP kit (Thermo Fisher Scientific, PI23610) as per manufacturer's instructions.
Immune blot analysis
Saturated overnight yeast cultures were diluted and grown to mid-log phase in YPD (with or without DOX) at 308C. Cells were harvested as described previously (LaFayette et al., 2010; Robbins et al., 2011) . In brief, cells were harvested by centrifugation and were washed with sterile ddH 2 O. Cell pellets were resuspended in lysis buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF and protease inhibitor cocktail (complete, EDTA-free tablet, Roche Diagnostics). Cells suspended in lysis buffer were mechanically disrupted by adding acid-washed glass beads and bead beating for 4 min. Protein concentrations were determined by Bradford analysis. Protein samples were mixed with one-sixth volume of 63 sample buffer containing 0.35 M Tris-HCl, 10% (wt/vol) SDS, 36% glycerol, 5% b-mercaptoethanol and 0.012% bromophenol blue for SDS-PAGE. Samples were boiled for 5 min, and then separated by SDS-PAGE using an 8% acrylamide gel. Proteins were electrotransferred to PVDF membranes (Bio-Rad Laboratories, Inc.) and blocked with 5% skimmed milk in phosphate buffered saline (PBS) with 0.1% tween. Blots were hybridized with antibodies against CaHsp90 (1:10 000), generously provided by Brian Larsen (Burt et al., 2003) , TAP (1:5000, Open Biosystems), Cdc28 (1:5000, anti-PSTAIRE, Santa Cruz Biotechnology, Santa Cruz, CA) or against alpha-tubulin (1:5000; AbD Serotec, MCA78G).
Microscopy
Imaging of cells cultured in liquid was performed using Differential Interference Contrast (DIC) microscopy using a Zeiss Axio Imager.MI and Axiovision software (Carl Zeiss, Inc.). Microscopy of colonies on solid media was performed using a Zeiss Stereo Discovery.V8.
Quantitative reverse transcription PCR
For monitoring RPD31 and HWP1 expression in KDAC mutants, overnight cultures were diluted and grown to midlog phase in YPD with or without 1 mg ml 21 of DOX. DOX treated cells were exposed to DOX for at least 6 h. RNA extraction was performed using a Qiagen RNeasy mini kit with the following the protocol: Frozen cell pellets were resuspended in 600 ll RLT lysis buffer containing bmercaptoethanol and 600 ll acid-washed silica beads in a 2 ml screw cap tube. Cells were mechanically disrupted by bead-beating for 30 s for four cycles with 1 min on ice between each cycle. Lysate (350 ll) was transferred to an eppendorf and centrifuged at max speed for 2 min. Lysate was transferred to a new eppendorf and 350 ll of 70% EtOH was added and mixed gently before solution was added to a spin column and centrifuged at max speed for 15 s. Flow through was discarded and the column was washed with 350 ll of RW1 buffer followed by two washes with 500 ll of RPE buffer. RNA was eluted from column with 87.5 ll of RNAse free ddH 2 O and treated with RNasefree DNase (QIAGEN). Purified RNA was immediately placed on ice or at 2808C for long-term storage. RNA concentration in samples was determined by Nanodrop and 2 lg of RNA was used for subsequent cDNA synthesis using the AffinityScript Multi Temperature cDNA Synthesis Kit (Agilent Technologies). RNA samples were only used for experiments if the RNA did not appear degraded when run on a 1% agarose gel and visualized by ethidium bromide staining. Quantitative reverse transcription PCR (qRT-PCR) was performed using FastSYBR Green Master Mix (Applied Biosystems) and BioRad CFX384 Real Time System, with the following cycling conditions: 958C for 3 min, then 958C for 10 s and 608C for 30 s, for 40 cycles. Reactions were performed in triplicate, for two biological replicates using the primers oLC2555/oLC2556 (RPD31), oLC750/oLC751 (HWP1), oLC752/oLC753 (GPD1) or oLC2285/oLC2286 (ACT1). Primer sequences are included in Supporting Information Table S3 . Data were analyzed using the BioRad CFX Manager 3.1. All data were normalized to the either GPD1 or ACT1 reference gene. Error bars show the standard error.
Growth curve assay
Overnight cultures were diluted to 10 3 cells ml 21 and used to inoculate wells to a final volume of 0.2 ml/well in 96-well microtiter plates (Sarstedt). Cells were grown in YPD at 308C with and without 65 mM of GdA. Optical density measurements (OD 600 ) were taken every 2 h for 72 h.
Glucocorticoid receptor activity assay
Overnight S. cerevisiae cultures were diluted and grown to mid-log phase in SD at 308C. Cultures were then diluted to OD 600 of 0.2 and added to 96-well microtiter plates (Sarstedt) at 50 ml per well. Cells were treated with or without 10mM deoxycorticosterone (Sigma D6875, dissolved in ethanol) for 1 h at 308C while shaking. About 100 ml of chlorophenol red-b-D-galactopyranoside (CPRG) substrate (100 mM Hepes, 150 mM NaCl, 5 mM L-aspartate, 10 g L 21 BSA, 0.05% Tween, 0.5% SDS, 1.2 mM CPRG (Roche 884308) dissolved in ddH 2 O, pH 7.25) were added to each well and shaken at 208C for 15 min. Absorption values were taken at OD 578 using a spectrophotometer.
Macrophage assay
C. albicans cells were incubated overnight in the presence or absence of 5 mg ml 21 DOX. ASC-mCherry macrophages (gift from Eicke Latz, (Franklin et al., 2014) ) were infected at an MOI of 3:1, as previously described . Macrophages were imaged 4 h post inoculation using a Zeiss Axio Observer.Z1 at 103 magnification. Pyroptosis events were determined by counting foci of red fluorescence, using ImageJ for quantification. Each experiment was performed in four technical replicates, with two biological replicates. At least 500 infected cells were counted per strain and condition. Statistical significance (P < 0.05) was determined by one-way ANOVA with Bonferroni corrections. 
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